Contact
searchSearch
HMP Global

RNAi Topic Center

News
Patisiran Shows Promise in Treating Hereditary Transthyretin Amyloidosis With Polyneuropathy
11/22/2024
Lisa Kuhns, PhD, MD
Patisiran offers promising benefits for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare and fatal genetic disorder characterized by amyloid fibril deposits affecting multiple organs.
Patisiran offers promising benefits for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare and fatal genetic disorder characterized by amyloid fibril deposits affecting multiple organs.
Patisiran offers promising...
11/22/2024
First Report Managed Care
News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
Lisa Kuhns, PhD, MD
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Unified Nomenclature for RNAi Therapeutics Reflects Growing Advances in Gene Silencing
10/23/2024
Lisa Kuhns, PhD, MD
RNAi therapeutics advance gene silencing with unified nomenclature.
RNAi therapeutics advance gene silencing with unified nomenclature.
RNAi therapeutics advance gene...
10/23/2024
First Report Managed Care
News
Experts Publish ATTRv Amyloidosis Recommendations for US Clinicians
10/09/2024
Jolynn Tumolo
Citing a lack of guidance in the United States addressing hereditary transthyretin (ATTRv; v for variant) amyloidosis with polyneuropathy, a group of 7 neurologists with expertise in ATTRv amyloidosis published recommendations for...
Citing a lack of guidance in the United States addressing hereditary transthyretin (ATTRv; v for variant) amyloidosis with polyneuropathy, a group of 7 neurologists with expertise in ATTRv amyloidosis published recommendations for...
Citing a lack of guidance in the...
10/09/2024
First Report Managed Care
News
Understanding the Pharmacology and Clinical Application of siRNA Therapies
09/25/2024
Hannah Musick
Explore the state of siRNA-based therapies, relevant pharmacology insights, and care strategies aimed to enhance patient outcomes.
Explore the state of siRNA-based therapies, relevant pharmacology insights, and care strategies aimed to enhance patient outcomes.
Explore the state of siRNA-based...
09/25/2024
First Report Managed Care
News
Exploring the Mechanisms of FDA-Approved siRNA Treatments in Disease Therapy
09/20/2024
Hannah Musick
Explore the groundbreaking advancements in RNA interference (RNAi) therapeutics, with a focus on the 6 US Food and Drug Administration (FDA)-approved small interfering RNA (siRNA) treatments and how they are revolutionizing disease treatment...
Explore the groundbreaking advancements in RNA interference (RNAi) therapeutics, with a focus on the 6 US Food and Drug Administration (FDA)-approved small interfering RNA (siRNA) treatments and how they are revolutionizing disease treatment...
Explore the groundbreaking...
09/20/2024
First Report Managed Care
News
Treatment Provides Relief for Recurrent Acute Hepatic Porphyria Attacks
03/04/2022
Jolynn Tumolo
Patients with recurrent attacks of acute hepatic porphyria had fewer attacks and less health care dependency after treatment with a double-stranded small interfering RNA.
Patients with recurrent attacks of acute hepatic porphyria had fewer attacks and less health care dependency after treatment with a double-stranded small interfering RNA.
Patients with recurrent attacks...
03/04/2022
First Report Managed Care
News
Treatment Proves Highly Effective for Primary Hyperoxaluria Type 1
02/17/2022
Maria Asimopoulos
Eighteen months of follow-up data suggested lumasiran was highly effective in treating a patient with primary hyperoxaluria type 1, a rare genetic disease.
Eighteen months of follow-up data suggested lumasiran was highly effective in treating a patient with primary hyperoxaluria type 1, a rare genetic disease.
Eighteen months of follow-up...
02/17/2022
First Report Managed Care
Industry Insights
News

What's New?

News
Patisiran Shows Promise in Treating Hereditary Transthyretin Amyloidosis With Polyneuropathy
11/22/2024
Lisa Kuhns, PhD, MD
Patisiran offers promising benefits for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare and fatal genetic disorder characterized by amyloid fibril deposits affecting multiple organs.
Patisiran offers promising benefits for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare and fatal genetic disorder characterized by amyloid fibril deposits affecting multiple organs.
Patisiran offers promising...
11/22/2024
First Report Managed Care
News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
Lisa Kuhns, PhD, MD
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Unified Nomenclature for RNAi Therapeutics Reflects Growing Advances in Gene Silencing
10/23/2024
Lisa Kuhns, PhD, MD
RNAi therapeutics advance gene silencing with unified nomenclature.
RNAi therapeutics advance gene silencing with unified nomenclature.
RNAi therapeutics advance gene...
10/23/2024
First Report Managed Care
News
Experts Publish ATTRv Amyloidosis Recommendations for US Clinicians
10/09/2024
Jolynn Tumolo
Citing a lack of guidance in the United States addressing hereditary transthyretin (ATTRv; v for variant) amyloidosis with polyneuropathy, a group of 7 neurologists with expertise in ATTRv amyloidosis published recommendations for...
Citing a lack of guidance in the United States addressing hereditary transthyretin (ATTRv; v for variant) amyloidosis with polyneuropathy, a group of 7 neurologists with expertise in ATTRv amyloidosis published recommendations for...
Citing a lack of guidance in the...
10/09/2024
First Report Managed Care
News
Understanding the Pharmacology and Clinical Application of siRNA Therapies
09/25/2024
Hannah Musick
Explore the state of siRNA-based therapies, relevant pharmacology insights, and care strategies aimed to enhance patient outcomes.
Explore the state of siRNA-based therapies, relevant pharmacology insights, and care strategies aimed to enhance patient outcomes.
Explore the state of siRNA-based...
09/25/2024
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use